BDS - Biology Derived Solutions

From nature to clinics to cure neuroblastoma

Keywords

  • Bio-tech
  • H&WB
  • Life Science
  • Med-Tech

Industries

Biotech

Abstract

Status: idea

Neuroblastoma comprises 15% of cancer deaths in children. Up to 50% of high-risk cases do not respond adequately to therapy, and current therapies have a multitude of side effects. BDS developed a panel of proteins with onco-suppressor role and a selection of peptides based on physiochemical properties (patent pending)

Info

Contatto: Giovanni Piccoli (giovanni.piccoli@unitn.it)